News

Selection News

2024.03.26
「動画で観るシンバイオ製薬」を更新しました。(Japanese only)
2024.03.26
第19期定時株主総会の動画を掲載しました。(Japanese only)
2024.02.26
Information on Shareholders' Meeting: Updated the Page
2024.02.20
Article on 2023 Earnings Call Featured in Nikkei Biotech Online (Japanese only)

Source: Nikkei Biotech ONLINE, 2024.02.15

Although Nikkei BP grants permission to use the articles, the content of the articles does not constitute a recommendation to purchase/invest in a specific company/organization or product/service.
Unauthorized reproduction, duplication, or electronic storage of the articles/photos/charts, etc. is prohibited.

2024.02.16
2023年12月期決算説明会の動画を掲載しました。(Japanese only)
2024.02.14
決算説明会資料(2023年12月期)(Japanese only)
2024.02.09
Analyst Report[Full report] (Shared Research)
2023.11.17
Notice of Relocation of Head Office
2023.11.06
SymBio To Present Positive Data from Ongoing Phase 2a Study of IV Brincidofovir in Adenovirus Infection in Oral Presentation at the 65th American Society of Hematology (ASH) Annual Meeting
2023.10.12
The Results of CRADA Study on Brincidofovir in Multiple Sclerosis Presented at the 9th Joint ECTRIMS-ACTRIMS Meeting
2023.07.20
Notice of Personnel Changes at SymBio Pharma USA, Inc.
2023.06.12
Presentation of the Results of Biomarker Research Predicting the Antitumor Effects of Brincidofovir at the 17th ICML
2023.05.29
IV Brincidofovir in Adenovirus Infection achieved POC in Phase 2 Clinical Trial
2023.04.24
SymBio enters into a CRADA to Assess Efficacy of Brincidofovir for Epstein-Barr Virus Associated Lymphoproliferative Disease
2023.03.22
Development of Brincidofovir for Multiple Sclerosis CRADA with the National Institute of Neurological Disorders and Stroke (NINDS)